2002 Annual Shareholder’s Meeting

12/11/2002


Click here to start


Table of Contents

2002 Annual Shareholder’s Meeting

Agenda 2002 Annual Shareholder’s Meeting

2002 Business Meeting

2002 Results and Future Goals

Forward-Looking Statements

2002 An Outstanding Year

2002 Results Versus Objectives

2003 First Quarter Results

Over 100,000 Catheters Sold!

AngioJet® Drive Units in Over 800 U.S. Hospitals! 95% of the top coronary labs have an AngioJet System.

Good News! Possis leads with 20% Market Share

More Good News! Realizable Markets Growing

STRATEGIES FOR INVESTING IN THE FUTURE

PPT Slide

PPT Slide

What is rapid exchange?

Improve system ease-of-use through current AngioJet® System upgrades

Development is underway on a future AngioJet® Drive Unit!

PPT Slide

PPT Slide

What is embolic protection?

Step 1: Clearing the way with AngioJet® thrombectomy

Step 2: Temporary Occlusion

Step 3: Debris Evacuation

AngioJet® + GuardDOG™ Embolic Protection System Regulatory Status

PPT Slide

PPT Slide

PPT Slide

PPT Slide

What is AngioJet Power-Pulse Spray?

PPT Slide

PPT Slide

Conclusions

Fiscal Year 2003 Primary Financial Goals

Post Market Clinical Studies

Current Studies

AJILE Study- Rationale

Can AngioJet save a night in the ICU? Should it be front-line therapy in PAO?

Why AJILE?

AJILE- Initial Results Presented Nov02

AJILE Study

Combination Thrombolysis and Thrombectomy for Treatment of Critical Limb Ischemia

PPT Slide

Why Power-Pulse Spray?

Power-Pulse Spray: AngioJet Xpeedior

Case study: (1) Subacute L iliac occlusion

(2) AngioJet delivered for P-PS

(3) Following 20 min P-PS

(4) Balloon angioplasty

(5) Final- PTA/Stent total procedure = 40 minutes

Before/After

Initial results: 18 patients, TCT02

Power-Pulse Spray- Conclusions

AngioJet Thrombectomy for Management of Deep Venous Thrombosis

Venous AngioJet Registry*

Venous registry, initial findings:

L superficial femoral vein DVT pre- and post AngioJet

R subclavian and axillary vein DVT Pre- and post AngioJet

AiMI Trial- in progress

AiMI Trial

AiMI- Nuclear endpoint AMI patient with severe inferior & septal defect:

AiMI- Current status, expectations

Post- market studies: Summary

Real World Experiences

Visit our website

Author: Michelle Jackson